Cardiff Oncology (CRDF) Projected to Post Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $0.09 million for the quarter. Investors interested in registering for the company's conference call can do so using this link.

Cardiff Oncology Stock Down 7.2 %

Cardiff Oncology stock traded down $0.33 during midday trading on Tuesday, reaching $4.23. The stock had a trading volume of 1,072,923 shares, compared to its average volume of 1,054,923. The firm has a market capitalization of $216.30 million, a PE ratio of -4.50 and a beta of 1.77. Cardiff Oncology has a 12 month low of $1.66 and a 12 month high of $6.42. The firm's 50-day moving average price is $4.07 and its 200 day moving average price is $3.20.

Insider Activity

In other Cardiff Oncology news, Director Gary W. Pace acquired 350,115 shares of the company's stock in a transaction that occurred on Wednesday, December 11th. The stock was bought at an average price of $2.60 per share, with a total value of $910,299.00. Following the completion of the purchase, the director now owns 1,047,876 shares of the company's stock, valued at approximately $2,724,477.60. This represents a 50.18 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 7.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on CRDF. Piper Sandler lifted their price objective on shares of Cardiff Oncology from $7.00 to $10.00 and gave the company an "overweight" rating in a research note on Friday, December 13th. HC Wainwright decreased their price objective on Cardiff Oncology from $14.00 to $13.00 and set a "buy" rating on the stock in a research note on Friday, November 8th.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.